Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citalopram vs Psychotherapy for Depression in Breast Cancer
NCT05063604Phase 2Terminated
- Sponsor
- Bellvitge University Hospital
- Start
- May 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of citalopram in major depressive disorder (MDD) (2 arms), sponsored by Bellvitge University Hospital. Primary endpoint: Change from Baseline in severity of depression on the Beck Depression Inventory (BDI) at 12 weeks. Started May 2022; status: terminated.
02
Drugs
citalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05063604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063604.